{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"11.4","value":"3.9"},{"groupId":"OG001","lowerLimit":"8.4","upperLimit":"58.3","value":"33.3"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"38.8","value":"16.7"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"33.1","value":"11.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"description":"Patients are grouped by the combination of clinical nodal response status and the post-treatment PET/CT finding (negative or positive). Nodal relapse rate is calculated for each group by the cumulative incidence method. Relapse is defined as reappearance of tumor after complete response. If possible, relapse should be confirmed by biopsy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Clinical nodal complete response; negative post-treatment PET/CT scan","id":"OG000","title":"Clinical CR + Negative PET"},{"description":"Did not have clinical nodal complete response; negative post-treatment PET/CT scan","id":"OG001","title":"No Clinical CR + Negative PET"},{"description":"Clinical nodal complete response; positive post-treatment PET/CT scan","id":"OG002","title":"Clinical CR + Positive PET"},{"description":"No clinical nodal complete response; positive post-treatment PET/CT scan","id":"OG003","title":"No Clinical CR + Positive PET"}],"paramType":"NUMBER","populationDescription":"Randomized eligible N2-3 patients with follow-up and PET data","reportingStatus":"POSTED","timeFrame":"From randomization to 2 years","title":"2-year Nodal Relapse Rates in Clinical N2-3 Patients by Post-treatment PET/CT Finding and Nodal Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}